Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
Tevogen Bio Holdings Inc. (NASDAQ: TVGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO [Yahoo! Finance]
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO